PEDIATRIC ONCOLOGY GROUP--THE CAROLINAS CONSORTIUM

儿科肿瘤学集团--卡罗莱纳州联盟

• 批准号: 2009114
• 负责人: JOSEPH LAVER
• 金额: $ 15.62万
• 依托单位: MEDICAL UNIVERSITY OF SOUTH CAROLINA
• 依托单位国家: 美国
• 财政年份: 1996
• 资助国家: 美国
• 起止时间: 1996-06-15 至 2000-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2009114
• 关键词: 6 thiopurine; Ewing's tumor; Hodgkin's disease; Wilms' tumor; XomaZyme; acivicin; acute leukemia; acute lymphocytic leukemia; acute myelogenous leukemia; adolescence (12-20); antineoplastics; asparaginase; astrocytoma; biological response modifiers; bone marrow transplantation; brain neoplasms; cancer registry /resource; cancer risk; central nervous system neoplasms; child (0-11); chronic myelogenous leukemia; cis platinum compound; clinical research; clinical trial phase I; colony stimulating factor; combination cancer therapy; combination chemotherapy; cooperative study; cyclophosphamide; cyclosporines; cytosine arabinoside; daunorubicin; deferoxamine; deoxycoformycin; doxorubicin; drug screening /evaluation; enalapril; ependymoma; etoposide; fazarabine; fluorouracil; germ cell neoplasms; glioma; hepatoblastoma; hepatocellular carcinoma; human genetic material tag; human immunodeficiency virus 1; human subject; human therapy evaluation; human tissue; ifosfamide; interferons; interleukin 2; medulloblastoma; melphalan; metastasis; methotrexate; minimal residual disease; mitoxantrone; molecular oncology; neoplasm /cancer chemotherapy; neoplasm /cancer classification /staging; neoplasm /cancer epidemiology; neoplasm /cancer genetics; neoplasm /cancer immunology; neoplasm /cancer immunotherapy; neoplasm /cancer pharmacology; neoplasm /cancer radiation therapy; neoplasm /cancer surgery; neuroblastoma; nonHodgkin's lymphoma; osteosarcoma; paclitaxel; pediatric pharmacology; podophyllin; prednisone; retinoate; rhabdomyosarcoma; tetrahydrofolylpolyglutamate synthase; tissue resource /registry; topotecan; trimetrexate; vincristine

DESCRIPTION (Adapted from the applicant's description): The institutions included in this proposal have been part of the Pediatric Oncology Group (POG) and received good performance scores during the past five years. There are two primary goals of this proposed research; the first is to accrue patients to the Group clinical trials in order to determine the optimal care of children with all types of cancers. The second is to contribute scientific expertise to the Group in areas of both patient care and tumor biology. This proposed research will allow participation in POG activities through a consortium effort of East Carolina University (ECU) School of Medicine, Carolinas Medical Center, Medical University of South Carolina (MUSC), Greenville Hospital, Presbyterian Hospital, and Memorial Mission Hospital (The Carolinas' Consortium). In addition to these clinical activities, their scientific efforts in next five years will include: (1) development of new protocols for the treatment of children with cancer focusing mainly on pediatric lymphomas; (2) expansion of studies of minimal marrow residual disease (using RT-PCR analysis) and assessment of new purging techniques in neuroblastoma; (3) participation in the laboratory evaluation of folylpolyglutamate synthetase (FPGS) in lymphoblasts of newly diagnosed patients; and (4) evaluation of the role hematopoietic growth factors in the treatment of pediatric malignancies.

描述（改编自申请人的描述）：机构 该提案中包括儿科肿瘤学组的成员 （POG）并在过去五年中获得了良好的绩效分数。 这项拟议研究有两个主要目标；第一个是 招募患者参加小组临床试验，以确定 为患有所有类型癌症的儿童提供最佳护理。 第二个是 为集团在患者护理领域贡献科学专业知识 和肿瘤生物学。 这项拟议的研究将允许参与 POG 由东卡罗来纳大学 (ECU) 联合开展的活动 南医科大学卡罗来纳医学中心医学院 卡罗莱纳州 (MUSC)、格林维尔医院、长老会医院和纪念馆 教会医院（卡罗来纳联盟）。 除了这些临床 活动，他们在未来五年的科学努力将包括：(1) 制定治疗儿童癌症的新方案 主要关注小儿淋巴瘤； (2) 拓展最小化研究 骨髓残留病（使用 RT-PCR 分析）和新的评估 神经母细胞瘤的清除技术； (3) 参与实验室 叶酰聚谷氨酸合成酶（FPGS）在新淋巴母细胞中的评价 确诊患者； (4)造血生长作用评价 小儿恶性肿瘤治疗的影响因素。